MJMyunghwa Jang

Myunghwa Jang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Myunghwa Jang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Gyuri Kim

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    3 shared publications
  • Jae Hyeon Kim

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    3 shared publications
  • Ji Yoon Kim

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    3 shared publications
  • Kyu Yeon Hur

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    3 shared publications
  • Rosa Oh

    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    3 shared publications
  • Sang-Man Jin

    Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    3 shared publications

Latest Publications

  • Open Access

    Steatotic Liver Disease Subtypes and Advanced Fibrosis as Independent Predictors of Ischemic Stroke in Type 2 Diabetes Mellitus

    by Myunghwa Jang, Gyuri Kim, Kyu-Na Lee, Rosa Oh, So Hyun Cho, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, et al.

    Although type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with an increased risk of ischemic stroke, the extent to which steatotic liver disease (SLD) subtypes and advanced liver fibrosis confer additional risk in individuals with T2DM remains unclear. We aimed to investigate the association of SLD categories and/or advanced liver fibrosis with ischemic stroke risk among patients with T2DM. A total of 2,220,249 patients with T2DM were classified into five groups: no steatosis, MASLD, MASLD with other combined disease, metabolic dysfunction and alcohol-related steatotic liver disease (MetALD), and alcohol-related liver disease (ALD) with metabolic dysfunction (MD). SLD was defined using a fatty liver index (FLI) of ≥30, and advanced fibrosis was defined by a BARD score of ≥2. Over a median follow-up of 11 years, 135,482 ischemic strokes (6.10%) occurred. Compared with no steatosis, adjusted hazard ratios (aHRs) for stroke were higher in MASLD (aHR, 1.10; 95% confidence interval [CI], 1.08 to 1.11), MASLD with combined disease (aHR, 1.14; 95% CI, 1.12 to 1.17), MetALD (aHR, 1.13; 95% CI, 1.11 to 1.16), and ALD with MD (aHR, 1.32; 95% CI, 1.27 to 1.37). Advanced fibrosis progressively increased stroke risk compared with non-SLD and non-fibrotic SLD. Compared with the FLI <30 group, those with FLI 30-60 and ≥60 showed increased aHRs for stroke. Very heavy drinking was associated with a further increase in risk compared with non-drinking. In patients with T2DM, all SLD categories and advanced liver fibrosis were associated with an increased risk of ischemic stroke. Very heavy alcohol consumption was generally associated with a higher stroke risk across FLI categories.

  • High-Amplitude and Prolonged Glucose Excursions as a Key Determinant of Discordance Between Glucose Management Indicator and Glycated Hemoglobin in Type 1 Diabetes

    by Soojin Park, So Hyun Cho, Seohyun Kim, Sang Ho Park, Ji Yoon Kim, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, et al.

    OBJECTIVE: Discordance between the glucose management indicator (GMI) and hemoglobin A1c (HbA1c) is frequently observed in diabetes, yet its physiological basis remains unclear. This study investigated how specific glucose excursion patterns captured by continuous glucose monitoring (CGM) contribute to this discordance in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Ninety-day CGM traces from 611 adults with type 1 diabetes were paired with HbA1c results obtained within ±15 days. Glucose excursions were quantified using the glucose rate increase detector (GRID) algorithm with varied peak glucose and time-to-peak thresholds. Discordance was defined using GMI-to-HbA1c and updated GMI (uGMI)-to-HbA1c ratios, and associations with GRID-derived excursion metrics were evaluated alongside conventional CGM-derived variability metrics. RESULTS: Excursions with peak glucose ≥250 mg/dL and time to peak ≥90 min were significantly associated with higher uGMI-to-HbA1c ratios after adjustment for age, sex, estimated glomerular filtration rate, and HbA1c group, with consistent findings across CGM devices (sensor type 1: β = 0.174, 95% CI 0.147–0.201; sensor type 2: β = 0.102, 95% CI 0.068–0.136; both P < 0.001) and alternative GMI formulations. In restricted cubic spline analyses, adjustment for GRID-derived excursion metrics differentially reshaped the associations of HbA1c, GMI, and uGMI with albuminuria and elevated triglyceride-glucose index in an outcome- and context-dependent manner, preferentially enhancing the informativeness of GMI and uGMI but not HbA1c. CONCLUSIONS: Frequent high and prolonged glucose excursions were consistently associated with GMI-HbA1c discordance across devices, HbA1c strata, and analytic conditions. GRID-derived excursion metrics modify the relationship between GMI/uGMI and glycemia-associated risk.


  • High incidence of eating disorders in individuals with type 2 diabetes and their association with cardiovascular and mortality risks

    by So Hyun Cho, Seohyun Kim, Rosa Oh, Ji Yoon Kim, Myunghwa Jang, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim

    Aims/hypothesis We examined the incidence of eating disorders (ED) in individuals with type 2 diabetes and their impact on all-cause mortality, composite CVD, cardiovascular (CV)-related mortality and CV-related hospitalisation. Methods This nationwide retrospective cohort study included 1,896,493 adults aged 20 years or older who underwent health examinations between 2013 and 2014. Time-varying Cox analyses were used to evaluate the effects of ED on all-cause mortality, composite CVD, CV-related mortality and CV-related hospitalisation in individuals with type 2 diabetes. Results The type 2 diabetes group demonstrated an increased incidence of ED (adjusted HR [aHR] 1.20 [95% CI 1.12, 1.28]) compared with the general population. Furthermore, the incidence of ED was higher among insulin users (aHR 1.30 [1.09, 1.54]) than among non-insulin users (aHR 1.18 [1.11, 1.27]). The type 2 diabetes with ED group showed an increased rate of all-cause mortality (aHR 2.57 [2.30, 2.87]), composite CVD (aHR 1.68 [1.44, 1.96]), CV-related mortality (aHR 2.68 [1.94, 3.70]), and CV-related hospitalisation (aHR 1.61 [1.37, 1.89]). Conclusions/interpretation Type 2 diabetes mellitus and ED increased all-cause mortality, composite CVD, CV-related mortality and CV-related hospitalisation. ED incidence was higher among insulin users with type 2 diabetes. Therefore, early diagnosis and personalised interventions are crucial to improve outcomes in this high-risk population. Graphical Abstract